Sanofi CEO Chris Viehbacher has been openly critical of his research operation in Toulouse, France. He said the researchers are costing too much money and haven't developed an important drug in 20 years.
The market for multiple sclerosis drugs is expected to reach nearly $20 billion by 2020, and Sanofi and Biogen Idec each want a big piece of that for their oral MS drugs.
Genzyme executives today rolled out positive data from a one-year extension study of its pivotal Phase III trial that gives the company some boasting rights for a drug that demonstrated a durable response in most patients.
Researchers at Genzyme have found a way to deliver drugs that shut down the genes associated with the neuromuscular disease myotonic dystrophy type 1, a type of muscular dystrophy.
A Sanofi plant that benefited from problems at its Genzyme subsidiary in the past is benefiting from Sanofi's good fortune now.
Genzyme, the biotech subsidiary of Sanofi, is experimenting with continuous processing, a new manufacturing approach that potentially can shave time, space and equipment costs by eliminating the batch approach to production.
Sanofi's ($SNY) Genzyme unit has set the price on its new rare-disease drug Kynamro: $176,000. That's steep, but it's part and parcel the super-niche-market strategy that's Big Pharma's new bread and butter.
The FDA came through with an approval for Kynamro, a treatment for a rare form of high cholesterol from Sanofi's ($SNY) Genzyme unit.
Manufacturing biotech drugs inside living cells is a complex and expensive task. But two big outfits, Amgen and Sanofi's Genzyme, are racing to develop a new process that promises to significantly reduce the cost of proteins and antibodies, according to a story in MIT's Technology Review.
Sanofi ($SNY) CEO Chris Viehbacher paid tribute to his Genzyme unit's MS drug candidate Lemtrada as the FDA accepted the company's application for its U.S. approval.